Benefits
Strength gains within 14 days — clinically proven
A statistically significant 15% improvement in bench press 1RM was demonstrated at just 14 days in RipFACTOR®'s first gold-standard RCT — an extremely rapid strength onset for a botanical ingredient. At 8 weeks, upper body strength improved up to 55% and lower body up to 31% in the ultra-performance group. These results occurred in resistance-trained males familiar with exercise, making them particularly credible.
Muscle gains exceeding double the exercise volume
In the second RCT, subjects taking RipFACTOR® at the performance dose showed strength and endurance gains comparable to the placebo group doing twice the exercise. At the ultra-performance dose, gains significantly exceeded the double-exercise placebo group — demonstrating that RipFACTOR® supplements exercise adaptation rather than simply adding stimulant-type acute effects.
Free testosterone elevation and anabolic hormone support
Both clinical studies confirmed improvements in testosterone:cortisol ratio favoring anabolism. A 19% increase in total testosterone and 30–40% increase in free testosterone at the ultra-performance dose represents meaningful hormonal support for muscle building and recovery — a genuine differentiator from other botanical muscle ingredients without hormonal evidence.
Endurance and time to exhaustion
Beyond strength, RipFACTOR® improved muscle endurance (repetitions to failure) and time to exhaustion — benefits relevant for both strength athletes seeking more reps and endurance athletes needing sustained output. This dual strength/endurance profile reflects the Mangifera indica bark's vascular and mitochondrial support mechanisms.
Mechanism of action
mTOR activation and testosterone:cortisol ratio optimization
Sphaeranthus indicus bioactives (sesquiterpene lactones, flavonoids) and Mangifera indica bark polyphenols work synergistically to activate mTOR/p70S6K muscle protein synthesis signaling, improve testosterone biosynthesis efficiency (Leydig cell function), and suppress cortisol-mediated protein catabolism. This combination shifts the anabolic:catabolic hormonal balance toward muscle growth while simultaneously providing direct intracellular anabolic signaling — explaining why RipFACTOR® outperforms double exercise volume in clinical assessment.
Clinical trials
Randomized, double-blind, placebo-controlled 8-week trial of RipFACTOR® (650 mg/day) in resistance-trained males. Outcomes: strength, endurance, testosterone. (2021)
40 male resistance-trained adults aged 18-40, 8-week double-blind clinical trial (Laila Nutraceuticals).
At 650 mg/day for 56 days: significant strength gains (1-RM bench/leg press, handgrip), increased free testosterone, improved time-to-exhaustion vs. placebo. Industry-funded (Laila); single-site Indian trial.
8-week clinical trial with efficiency model design comparing RipFACTOR® at two doses vs placebo and placebo with double exercise volume.
99 young men (age 22±3), 4-arm 8-week clinical trial comparing 425 mg or 850 mg SMI vs placebo with 1 or 2 RET sets (McGill/PLT-funded).
At 425 mg (Performance) and 850 mg (Ultra-Performance): augmented bench-press/leg-extension strength and reps-to-failure vs RET alone; ultra-performance dose exceeded double-exercise placebo group. Free testosterone elevated. Industry-funded.